Parkinson disease and growth factors — is GDNF good enough?

TY - JOUR

T1 - Parkinson disease and growth factors — is GDNF good enough?

AU - Kirkeby, Agnete

AU - Barker, Roger A.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

AB - Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

UR - http://www.scopus.com/inward/record.url?scp=85064011594&partnerID=8YFLogxK

U2 - 10.1038/s41582-019-0180-6

DO - 10.1038/s41582-019-0180-6

M3 - Comment/debate

C2 - 30948845

AN - SCOPUS:85064011594

SN - 1759-4758

VL - 15

SP - 312

EP - 314

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

IS - 6

ER -